Our Partnerships with Pharmaceutical Companies
Partnering with Johnson & Johnson Innovative Medicine
In 2021, we were thrilled to enter into a collaboration agreement with Johnson & Johnson Innovative Medicine.
Our goal as partners is to identify patients with amyloidosis with cardiac involvement from routine echocardiograms.
We’ve since worked with the data science and oncology researchers at Johnson & Johnson Innovative Medicine to create an AI tool to promote the screening of patients at risk for the potential build-up of amyloid, an abnormal protein, in the heart.
The platform, EchoGo® Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis using only a single commonly acquired ultrasound view of the heart.
EchoGo® Amyloidosis has since been granted FDA Breakthrough Device Status for detecting the disease.
We continue to work closely with Johnson & Johnson Innovative Medicine as we prepare further regulatory submissions for the U.S., and the device could be approved for commercialization as soon as early 2024.
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
Ultromics has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis.
The platform, EchoGo Amyloidosis®, uses artificial intelligence to analyse echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart.
"When applied to routine tests like echocardiograms, artificial intelligence is demonstrating exciting potential to help facilitate earlier disease detection – with the goal of connecting patients with treatment sooner and, ultimately, driving better health outcomes."
Najat Khan, Ph.D.
Chief Data Science Officer and Global Head, Strategy & Operations at Janssen Research & Development, LLC.
